

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/010384

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 G01N33/74 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, Sequence Search, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	YAMAUCHI T ET AL: "Cloning of adipopectin receptors that mediate antidiabetic metabolic effects" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 423, 12 June 2003 (2003-06-12), pages 762-769, XP002277646 ISSN: 0028-0836 cited in the application	1-17
A	page 767, column 2, paragraph 3 - page 768, column 1, paragraph 2; figure 1	18-25
A	WO 03/023008 A (MILLER CHARLES E; SPYTEK KIMBERLY A ; VERNET CORINE A M (US); KEKUDA R) 20 March 2003 (2003-03-20) page 143 - page 145 pages 346-349	1-25
	----- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

17 January 2005

Date of mailing of the international search report

22 JUN 2005

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Vadot-Van Geldre, E

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	<p>TIETGE UWE J F ET AL: "Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics." AMERICAN JOURNAL OF PHYSIOLOGY. ENDOCRINOLOGY AND METABOLISM. JUL 2004, vol. 287, no. 1, July 2004 (2004-07), pages E82-E89, XP008041584 ISSN: 0193-1849 abstract</p>	1-25
A	<p>-----</p> <p>XU AIMIN ET AL: "The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice." JOURNAL OF CLINICAL INVESTIGATION, vol. 112, no. 1, July 2003 (2003-07), pages 91-100, XP002313703 ISSN: 0021-9738 pages 91,99</p> <p>-----</p>	1-25

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2004/010384

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 26
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-25 all partially

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-25 (all partially)

AdipoR1 in methods for screening for therapeutic agents useful in the treatment of spleen liver cirrhosis vs healthy spleen, in methods of diagnosis of said disease, pharmaceutical compositions containing therapeutic agents for the treatment of said disease, their production and their use

2. claims: 1-25 (all partially)

AdipoR1 in methods for screening for therapeutic agents useful in the treatment of stomach tumor, in methods of diagnosis of said disease, pharmaceutical compositions containing therapeutic agents for the treatment of said disease, their production and their use

3. claims: 1-25 (all partially)

AdipoR1 in methods for screening for therapeutic agents useful in the treatment of rectum tumor, in methods of diagnosis of said disease, pharmaceutical compositions containing therapeutic agents for the treatment of said disease, their production and their use

4. claims: 1-25 (all partially)

AdipoR1 in methods for screening for therapeutic agents useful in the treatment of diseased Jurkat (T-cells) vs healthy T-cells peripheral blood CD4+, in methods of diagnosis of said disease, pharmaceutical compositions containing therapeutic agents for the treatment of said disease, their production and their use

5. claims: 1-25 (all partially)

AdipoR1 in methods for screening for therapeutic agents useful in the treatment of prostate tumor, in methods of diagnosis of said disease, pharmaceutical compositions containing therapeutic agents for the treatment of said disease, their production and their use

6. claims: 1-25 (all partially)

BEST AVAILABLE COPY

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

AdipoR1 in methods for screening for therapeutic agents useful in the treatment of diseased HEK293 versus healthy kidney, in methods of diagnosis of said disease, pharmaceutical compositions containing therapeutic agents for the treatment of said disease, their production and their use

7. claims: 1-25 (all partially)

AdipoR1 in methods for screening for therapeutic agents useful in the treatment of lung COPD, in methods of diagnosis of said disease, pharmaceutical compositions containing therapeutic agents for the treatment of said disease, their production and their use

8. claims: 1-25 (all partially)

AdipoR1 in methods for screening for therapeutic agents useful in the treatment of prostate benign prostate hyperplasia, in methods of diagnosis of said disease, pharmaceutical compositions containing therapeutic agents for the treatment of said disease, their production and their use

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/010384

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 03023008 A	20-03-2003	CA 2451454 A1	20-03-2003
		JP 2005512515 T	12-05-2005
		WO 03023008 A2	20-03-2003
		US 2004067490 A1	08-04-2004
		US 2005049192 A1	03-03-2005

BEST AVAILABLE COPY